Cargando…
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder
NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and twenty subjects were randomized...
Autores principales: | Papakostas, G. I., Johe, K., Hand, H., Drouillard, A., Russo, P., Kay, G., Kashambwa, R., Hoeppner, B., Flynn, M., Yeung, A., Martinson, M. A., Fava, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303010/ https://www.ncbi.nlm.nih.gov/pubmed/30626911 http://dx.doi.org/10.1038/s41380-018-0334-8 |
Ejemplares similares
-
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
por: Fava, M, et al.
Publicado: (2016) -
Erratum: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
por: Fava, M, et al.
Publicado: (2016) -
NSI‐189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats
por: Tajiri, Naoki, et al.
Publicado: (2017) -
Enhancement of Mitochondrial Function by the Neurogenic Molecule NSI-189 Accompanies Reversal of Peripheral Neuropathy and Memory Impairment in a Rat Model of Type 2 Diabetes
por: Jolivalt, C. G., et al.
Publicado: (2022) -
Behavioral and Histopathological Assessment of Adult Ischemic Rat Brains after Intracerebral Transplantation of NSI-566RSC Cell Lines
por: Tajiri, Naoki, et al.
Publicado: (2014)